FDA to Review Zanidatamab BLA for HER2+ Metastatic Biliary Tract Cancer

News
Article

A rolling BLA for zanidatamab in previously treated, HER2-positive, advanced biliary tract cancer has been submitted to the FDA.

FDA

FDA

A rolling biologics license application (BLA) seeking the approval of zanidatamab (ZW25) for the treatment of patients with previously treated, HER2-positive, unresectable, locally advanced, or metastatic biliary tract cancer has been completed and submitted to the FDA.1

The submission is based on data from the phase 2b HERIZON-BTC-01 trial (NCT04466891), which demonstrated that patients with HER2-positive biliary tract cancer treated in cohort 1 (n = 80) experienced a confirmed objective response rate (ORR) of 41.3% (95% CI, 30.4%-52.8%) by independent review committee (IRC) assessment, which included a complete response (CR) rate of 1.3% and a partial response (PR) rate of 40%; 27.5% of patients achieved stable disease (SD), 30% had progressive disease (PD), and 1.3% were not evaluable for response.2

“This important milestone brings us one step closer to delivering zanidatamab, a targeted treatment option, to patients living with HER2-positive biliary tract cancer, a type of cancer that is associated with a 5-year overall survival [OS] rate of less than 5%,” Rob Iannone, MD, MSCE, executive vice president and global head of research and development at Jazz Pharmaceuticals, stated in a news release.1

HERIZON-BTC-01 enrolled patients with locally advanced or metastatic biliary tract cancer, and tissue was required to confirm HER2 status via central laboratory. Other key inclusion criteria included PD after treatment with a gemcitabine-based regimen, no prior treatment with HER2-targeted therapies, and an ECOG performance status of 0 or 1.2 Patients with HER2-positive biliary tract cancer, defined as immunohistochemistry (IHC) 2+ or 3+, were enrolled to cohort 1. Cohort 2 included patients with a HER2 status of IHC 0 or 1+.3

All patients received zanidatamab monotherapy at 20 mg/kg once every 2 weeks. Every 8 weeks, patients underwent assessment via CT or MRI.

Confirmed ORR by ICR assessment in cohort 1 served as the trial’s primary end point. Secondary end points included duration of response (DOR), disease control rate (DCR), progression-free survival (PFS), OS, and safety.

In cohort 1, the median age was 64 years (range, 58-70) and 56% of patients were female. More than half of patients were Asian (65%), from Asia (63%), and had an ECOG performance status of 1 (73%).3 Regarding disease subtypes, 51% had gallbladder cancer, 29% had intrahepatic cholangiocarcinoma, and 20% had extrahepatic cholangiocarcinoma. Eighty-nine percent of patients had American Joint Committee on Cancer stage IV disease at the time of study entry. Most patients had HER2 3+ disease status by IHC (78%) and the remainder had HER2 2+ status (23%).

Patients had received a median of 1 prior line of therapy for metastatic or locally advanced disease. Prior systemic treatment included a gemcitabine-based regimen (100%), gemcitabine plus cisplatin (76%), fluoropyrimidine-based treatment (34%), a PD-1/PD-L1 inhibitor (26%), or fluoropyrimidine (6%). Moreover, 16% of patients previously received radiotherapy and 31% previously underwent curative-intent surgery.

Additional efficacy data from cohort 1 showed that the median time to first response by ICR assessment was 1.8 months (95% CI, 1.7-2.0), and the median DOR was 12.9 months (95% CI, 6.0-not estimable). Notably, 81.8% of patients experienced a duration of response of at least 16 weeks. The ICR-assessed DCR was 68.8% (95% CI, 57.4%-78.7%). The median PFS was 5.5 months (95% CI, 2.7-7.2).2

Per investigator assessment, the ORR achieved with the agent was also 41.3% (95% CI, 30.4%-52.8%), with CR, PR, SD, and PD rates of 5%, 36.3%, 26.3%, and 31.3%, respectively. The median time to first response was also 1.8 months (95% CI, 1.6-3.7), and the median DOR was 11.1 months (95% CI, 5.6-14.1). The investigator-assessed DCR was 67.5% (95% CI, 56.1%-77.6%), and the median PFS by investigator assessment was 5.4 months (95% CI, 3.6-7.2).

Regarding safety, at least 1 treatment-emergent adverse effect (AE) was experienced by 97% of patients, with 72% of patients experiencing at least 1 effect determined by the investigator to be related to zanidatamab. The most common treatment-related AEs (TRAEs) included diarrhea (grade 1/2, 32%; grade 3, 5%), infusion-related reaction (32%; 1%), decreased ejection fraction (6%; 3%), nausea (8%; 1%), increased alanine aminotransferase (7%; 0%), increased aspartate aminotransferase (6%; 1%), vomiting (7%; 0%), fatigue (6%; 0%), anemia (2%; 2%), hypokalemia (1%; 1%), decreased platelet count (1%; 1%), increased blood bilirubin (0%; 1%), enteritis (0%; 1%), increased lipase (0%; 1%), oral candidiasis (0%; 1%), pneumonitis (0%; 1%), and stomatitis (0%; 1%).

“Zanidatamab is a biparatopic HER2-targeted bispecific antibody that simultaneously binds two non-overlapping epitopes of HER2 resulting in multiple mechanisms of action,” Iannone added.1 “Second-line biliary tract cancer represents the first of multiple indications we are evaluating and we are excited about zanidatamab's potential as a new option for multiple HER2-expressing cancers, with ongoing phase 3 trials in first-line biliary tract, first-line gastroesophageal adenocarcinoma, and previously treated breast cancer."

References

  1. Jazz Pharmaceuticals completes zanidatamab biologics license application for previously treated HER2-positive metastatic biliary tract cancer. News release. Jazz Pharmaceuticals. April 2, 2024. Accessed April 2, 2024. https://investor.jazzpharma.com/news-releases/news-release-details/jazz-pharmaceuticals-completes-zanidatamab-biologics-license
  2. Pant S, Fan J, Oh D-Y, et al. Results from the pivotal phase (Ph) 2b HERIZON-BTC-01 study: Zanidatamab in previously-treated HER2‑amplified biliary tract cancer (BTC). J Clin Oncol. 2023;41(suppl 16):4008. doi:10.1200/JCO.2023.41.16_suppl.4008
  3. Harding JJ, Fan J, Oh D-Y, et al. Zanidatamab for HER2-amplified, unresectable, locally advanced or metastatic biliary tract cancer (HERIZON-BTC-01): a multicentre, single-arm, phase 2b study. Lancet Oncol. 2023;24(7):772-782. doi:10.1016/S1470-2045(23)00242-5
Related Videos
Video 6 - "Patient Case 2: A 62-Year-Old Woman with Metastatic Rectal Cancer"
Video 5 - "Adverse Events Associated With TAS-102 Plus Bevacizumab in CRC"
Michael J. Overman, MD
Ilyas Sahin, assistant professor, Medicine, Department of Medicine, Division of Hematology & Oncology, University of Florida College of Medicine
Michael J. Overman, MD
Manish A. Shah, MD, director, Gastrointestinal Oncology Program, Weill Cornell Medicine; chief, Solid Tumor Service, co-director, Center for Advanced Digestive Disease, NewYork Presbyterian
Katrina S. Pedersen, MD, MS
Efrat Dotan, MD
In this fifth episode of OncChats: Leveraging Immunotherapy in GI Malignancies, Toufic Kachaamy, MD, of City of Hope, Sunil Sharma, MD, of City of Hope, and Madappa Kundranda, MD, PhD, of Banner MD Anderson Cancer Center, discuss next steps for research, including vaccination strategies, personalized cellular therapies, and more.
In this fourth episode of OncChats: Leveraging Immunotherapy in GI Malignancies, experts discuss research efforts being made with organoids to address existing questions with immunotherapy and the exploration of multimodality approaches to improve outcomes.